论文部分内容阅读
目的观察肺特灵Ⅲ对博莱霉素致小鼠肺纤维化的干预作用。方法通过气管内注射博莱霉素制作小鼠肺纤维化模型,给予肺特灵Ⅲ灌胃(ig)治疗14d后,进行肺系数、肺组织病理形态及羟脯氨酸(HYP)、总抗氧化能力(T-AOC)、丙二醛(MDA)、谷胱甘肽(GSH)等血清和肺组织中生化指标水平的测定和分析,观察肺特灵Ⅲ对小鼠肺纤维化的影响。结果经肺特灵Ⅲ治疗后,与模型组相比,各组小鼠肺系数和HYP含量显著降低,小鼠血清中T-AOC增强、MDA含量明显降低,肺组织中GSH含量明显增加,肺泡炎和肺纤维化程度明显减轻。上述变化均有统计学意义(皆P<0.05或<0.01)。结论肺特灵Ⅲ对博莱霉素致鼠肺纤维化早期病变有一定的治疗作用,其机制可能与抑制炎症细胞的浸润活化、抗氧化作用及抑制胶原的形成有关。
Objective To observe the effect of Lifeline Ⅲ on bleomycin-induced pulmonary fibrosis in mice. Methods Pulmonary fibrosis model was induced by intratracheal instillation of bleomycin. After 14 days of treatment with Flos Lonicerae ig (ig), the lung coefficient, pulmonary pathology, hydroxyproline (HYP) (T-AOC), malondialdehyde (MDA), glutathione (GSH) and other serum and lung biochemical indicators of the level of determination and analysis to observe the effect of Fondang III on pulmonary fibrosis in mice. Results Compared with the model group, the pulmonary coefficient and HYP content of mice in each group were significantly decreased after TFC treatment, the serum T-AOC levels were increased, the content of MDA was significantly decreased, the content of GSH in lung tissue was significantly increased, Inflammation and pulmonary fibrosis significantly reduced. The above changes were statistically significant (all P <0.05 or <0.01). Conclusion Pulcotin Ⅲ has a certain therapeutic effect on the early stage of bleomycin-induced pulmonary fibrosis in rats, and its mechanism may be related to the inhibition of infiltration and activation of inflammatory cells, antioxidation and the inhibition of the formation of collagen.